Patents Issued in February 9, 2021
-
Patent number: 10912814Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.Type: GrantFiled: June 1, 2017Date of Patent: February 9, 2021Assignee: Gilead Pharmasset LLCInventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
-
Patent number: 10912815Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on binding of dynamin-1-related protein (Drp1) GTPase activity, Drp1 to mitochondrial fission 1 protein (Fis1), reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.Type: GrantFiled: January 4, 2018Date of Patent: February 9, 2021Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daria Mochly-Rosen, Xin Qi, Nir Qvit
-
Patent number: 10912816Abstract: The invention provides for methods of treating obesity or an obesity-associated disorder.Type: GrantFiled: April 15, 2013Date of Patent: February 9, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: José Leonardo Walewski, Paul David Berk
-
Patent number: 10912817Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at room temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.Type: GrantFiled: February 20, 2019Date of Patent: February 9, 2021Assignee: NoNO Inc.Inventor: Jonathan David Garman
-
Patent number: 10912818Abstract: The invention relates to acetylcholine-producing microorganisms for use in the prevention and/or treatment of intestinal diseases, and/or reduction of risks of intestinal diseases, and/or improvement of intestinal health as well as promoting healthy gut flora. The acetylcholine-producing microorganisms may be provided as a pharmaceutical dosage form or as additive to functional food or food supplemental products. Also encompassed is a method for the production of acetylcholine by use of Lactobacilli. Further the invention refers to microbially produced acetylcholine for use in the treatment and/or prevention of intestinal diseases.Type: GrantFiled: August 4, 2017Date of Patent: February 9, 2021Assignee: Ludwig Stocker Hofpfisterei GmbHInventors: Jürgen Mayer, Dirk Haller, Anna Zhenchuk, Thomas Hofmann, Andreas Dunkel, Michael Schemann, Dagmar Krüger
-
Patent number: 10912819Abstract: This invention provides a novel formulation for effective delivery of a pharmaceutically active ingredient such as a peptide possessing neuroprotective activity. Also provided are methods for treating pertinent clinical implications such as autism, schizophrenia, and dementia using the formulation.Type: GrantFiled: January 24, 2017Date of Patent: February 9, 2021Assignee: Ramot at Tel-Aviv University, Ltd.Inventor: Illana Gozes
-
Patent number: 10912820Abstract: A method for selecting an immunomodulatory kit, selected for an individual patient, for use in the treatment of patients suffering from myeloid leukemias. Different kits are available for selection and ex vivo testing which are composed of substances that have different immunomodulatory effects on leukemia cells. Each kit particularly contains GM-CSF and one (or two) more substances, selected from PICIBANIL, PGE1, PGE2, CALCIMYCIN and TNF?, as well as pharmaceutically acceptable adjuvants. The clinical aim is to modify, once the individually selected immunomodulatory kits were administered, blast cells in the body of the patient such that they turn into a “vaccine” which is able to activate the immunoreactive cells (of the patient or of the stem cell donor) in the body against blast cells.Type: GrantFiled: April 18, 2018Date of Patent: February 9, 2021Assignee: Modiblast Pharma GmbHInventor: Helga Schmetzer
-
Patent number: 10912821Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.Type: GrantFiled: January 27, 2020Date of Patent: February 9, 2021Assignee: MannKind CorporationInventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson
-
Patent number: 10912822Abstract: Devices for guided tissue regeneration (GTR) include a matrix of chitosan and mutable collagenous tissue (MCT) wherein the chitosan is electrostatically bonded to the MCT to form MCT-chitosan composite material. The MCT can be isolated from invertebrate marine organisms, such as sponges, jellyfish, mollusks and echinoderms. The MCT-chitosan composite material can be formulated as a biofilm, a 3D-sponge, a hydrogel, or as an electrospun nanofiber, or the MCT-chitosan composite material can coat a biomaterial surface. The devices can include wound dressings and tissue sponges, including 3D sponges. Applications include tissue engineering and wound healing, as well as burns and other related guided tissue regeneration applications. MCT and MCT-chitosan composite material, contained in a pharmaceutically acceptable topical carrier, also has cosmeceutical applications, for treating scars, as well as skin discoloration and various pigmentation issues, including melasma/chloasma.Type: GrantFiled: September 6, 2018Date of Patent: February 9, 2021Assignee: Marine Essence Biosciences Corporation of USAInventors: Danny Qiu, Sergio Madrigal Carballo
-
Patent number: 10912823Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.Type: GrantFiled: May 30, 2018Date of Patent: February 9, 2021Assignee: Allergan, Inc.Inventors: Birgitte P.S. Jacky, Shiazah Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
-
Patent number: 10912824Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.Type: GrantFiled: July 13, 2015Date of Patent: February 9, 2021Assignees: Ospedale San Raffaele S.r.l., Fondazione TelethonInventors: Alessio Cantore, Angelo Leone Lombardo, Luigi Naldini
-
Patent number: 10912825Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.Type: GrantFiled: January 14, 2019Date of Patent: February 9, 2021Assignee: KJ Biosciences LLCInventors: Yawei Ni, Jianhua Guo
-
Patent number: 10912826Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.Type: GrantFiled: July 24, 2020Date of Patent: February 9, 2021Assignee: CureVac AGInventors: Andreas Thess, Thomas Schlake, Jochen Probst
-
Patent number: 10912827Abstract: The present invention relates to an improved recombinant vaccination vector for the treatment or vaccination against hepatitis B virus (HBV) as well as pharmaceutical compositions or vaccines comprising said recombinant vaccination vector. The present invention also relates to a recombinant vaccination vector for use in a method of vaccination against HBV, as well as kits comprising a vaccine comprising the recombinant vaccination vector.Type: GrantFiled: January 12, 2017Date of Patent: February 9, 2021Assignee: HELMHOLTZ ZENTRUM MÜNCHEN—DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Ulrike Protzer, Tanja Bauer, Anna Kosinska, Martin Mueck-Haeusl
-
Patent number: 10912828Abstract: The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: March 2, 2020Date of Patent: February 9, 2021Assignee: AGENUS INC.Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
-
Patent number: 10912829Abstract: Methods, apparatus, and systems are provided for tracking freight. Embodiments include a tracking device for a trailer containing a load. The tracking device may include a housing including a connector, a main body, and a GPS tracker located within the main body and configured to track the location of the load. Tracking device may include a support member linking the connector and main body. Connector may securely attach to a container on the trailer and attach to a seal such that the container cannot be opened without breaking the seal. Support member may stabilize the housing and protect the tracking device during transit of the load. A tracking system may implement to monitor, gather information and report on the tracking device and the load.Type: GrantFiled: October 15, 2015Date of Patent: February 9, 2021Assignee: CRC R&D, LLCInventor: Ronald H. Mains
-
Patent number: 10912830Abstract: The inventive subject matter relates to novel antibodies to lacritin splice variants, improved methods for detecting lacritin splice variants, and methods for diagnosing Sjögren's Syndrome.Type: GrantFiled: February 1, 2018Date of Patent: February 9, 2021Assignee: JAMES MADISON INNOVATIONS, INC.Inventors: Robert L McKown, Kyle Seifert, Ronald W Raab
-
Patent number: 10912831Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: September 24, 2020Date of Patent: February 9, 2021Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
-
Patent number: 10912832Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.Type: GrantFiled: November 27, 2019Date of Patent: February 9, 2021Assignee: ACADEMIA SINICAInventors: Patrick C. H. Hsieh, Pei-Jung Wu, Steve Roffler, Bill Cheng
-
Patent number: 10912833Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.Type: GrantFiled: April 20, 2018Date of Patent: February 9, 2021Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, David B. Thompson, John Anthony Zuris
-
Patent number: 10912834Abstract: Compositions containing a complex that contains a cation with alkyl chains and a macromolecule anion, and methods of making and using are disclosed. The compositions are typically charge neutral and a liquid at room temperature and standard pressure. The macromolecule anions may be nucleic acids, peptides, proteins, and/or carbohydrates. The compositions have enhanced penetration across the skin barrier (stratum corneum) and into the skin cells, delivering the macromolecules to the skin cells. The compositions are topically applied to the skin and are particularly useful for treatment of skin conditions.Type: GrantFiled: August 29, 2017Date of Patent: February 9, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael Zakrewsky, Samir Mitragotri
-
Patent number: 10912835Abstract: Pharmaceutical coatings obtained from coating compositions based on film-forming copolymers of N,N-diethylaminoethyl methacrylate (DEAEMA) and methyl methacrylate (MMA) comprising a weight ratio of DEAEMA:MMA in the range of 35:65 to 55:45, where the copolymers are present partially neutralized with C3-C10-dicarboxylic acids.Type: GrantFiled: December 20, 2017Date of Patent: February 9, 2021Assignee: BASF SEInventors: Karl Kolter, Silke Gebert, Michael Klemens Müller, Maximilian Angel
-
Patent number: 10912836Abstract: The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (PSMA) and a FC receptor binding moiety which modulates an FC immune receptor, preferably a Fc?RI receptor. Compounds according to the present invention bind selectively to cancer cells which upregulate PSMA and through that interaction, place the Fc receptor binding moiety of the compound in proximity to a Fc receptor, preferably a Fc?RI receptor, which can modulate (preferably, upregulate) a humoral response in a patient to cancer cells. Through this biological action of the compounds according to the present invention, cancer cells, including metastatic cancer cells, especially prostate cancer cells can be immune regulated, resulting in the favorable therapy of cancer in a patient.Type: GrantFiled: November 5, 2018Date of Patent: February 9, 2021Assignee: YALE UNIVERSITYInventors: David A. Spiegel, Patrick McEnaney, Kelly Fitzgerald
-
Patent number: 10912837Abstract: Provided are methods for linking polypeptides (including peptides and proteins) to other moieties using radical imitated thiol-ene chemistries, for example, modifying a polypeptide by introducing reactive thiol groups and reacting the thiol groups with olefin-containing reagents or alkyne-containing reagents under conditions that support radical thiol-ene or thiol-yne reactions. The reactive thiol groups have greater activity for radical thiol-ene reactions that a cysteine thiol group, including thiol groups that are separated from the peptide backbone by at least two carbon atoms, for example, the thiol group of a homocysteine residue. Also provided are compositions and biomaterials containing the linked polypeptides, for example, peptide and protein conjugates, and thiol-ene based biocompatible hydrogel polymers, and their uses in the medical field.Type: GrantFiled: February 9, 2016Date of Patent: February 9, 2021Assignee: MOSAIC BIOSCIENCES, INC.Inventors: Alexei V. Kazantsev, Peter D. Mariner, Martin Stanton
-
Patent number: 10912838Abstract: The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand.Type: GrantFiled: February 22, 2018Date of Patent: February 9, 2021Assignees: THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITYInventors: Kazunori Kataoka, Yasutaka Anraku, Nobuhiro Nishiyama, Kanjiro Miyata, Takehiko Ishii, Yu Matsumoto, Yu Fukusato, Akihiro Mizoguchi, Takanori Yokota, Hiroya Kuwahara, Kazutaka Nishina, Hidehiro Mizusawa
-
Patent number: 10912839Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.Type: GrantFiled: March 1, 2018Date of Patent: February 9, 2021Assignee: ELLIPSES PHARMA LIMITEDInventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
-
Patent number: 10912840Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.Type: GrantFiled: May 11, 2018Date of Patent: February 9, 2021Assignee: ENDOCYTE, INC.Inventors: Iontcho Radoslavov Vlahov, Joseph Anand Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson, Marilynn Vetzel, Christopher Paul Leamon
-
Patent number: 10912841Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.Type: GrantFiled: January 31, 2018Date of Patent: February 9, 2021Assignee: PIERRE FABRE MEDICAMENTInventors: Ian Rilatt, Michel Perez, Marie Lamothe
-
Patent number: 10912842Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.Type: GrantFiled: June 9, 2016Date of Patent: February 9, 2021Assignee: Seattle Genetics, Inc.Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman
-
Patent number: 10912843Abstract: A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91phox protein. The transgenic mouse can serve as a model for human chronic granulomatous disease.Type: GrantFiled: January 31, 2019Date of Patent: February 9, 2021Assignee: National Cheng Kung UniversityInventors: Chi-Chang Shieh, Chia-Liang Yen, Dar-Bin Shieh, Si-Tse Jiang
-
Patent number: 10912844Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof:Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.Type: GrantFiled: November 22, 2019Date of Patent: February 9, 2021Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Michael Heartlein
-
Patent number: 10912845Abstract: The present invention relates to an improved method of providing photoreceptor function to a cell, for example for use in the treatment of retinal degeneration. The present invention also relates to compositions and kits, in particular for use in such methods.Type: GrantFiled: February 24, 2015Date of Patent: February 9, 2021Assignee: The University of ManchesterInventors: Robert Lucas, Paul Bishop, Jasmina Cehajic-Kapetanovic
-
Patent number: 10912846Abstract: Chemiluminescence imaging probes for in vivo detection of biological molecules, events, or processes. The CLI probes may feature a portion of a fluorescein molecule and a portion of a luminol molecule. The fluorescein molecule and luminol molecule may be linked by a non-xanthenic aromatic ring. The CLI probes are generally non-toxic and soluble in aqueous solutions such as PBS. The CLI probes may be used to detect specific molecules in vivo.Type: GrantFiled: May 27, 2016Date of Patent: February 9, 2021Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Zhiping Zheng, Jiagen Lv, Yingchun Nie, Wansheng Liang
-
Patent number: 10912847Abstract: The present invention relates to a compressed solid composition for MRI comprising a physiologically acceptable manganese (II) compound, its preparation and use for preparing an oral solution.Type: GrantFiled: June 8, 2020Date of Patent: February 9, 2021Assignee: Ascelia Pharma ABInventors: Bent Højgaard, Magnus Olafsson Corfitzen, Dorthe Da Graca Couto Thrige
-
Patent number: 10912848Abstract: The present invention provides a dual-purpose photoacoustic tomography (PAT)/ultrasound contrast agent comprising: (a) a micro-bubble containing gas and porphyrin therein; and (b) nanoparticles bound on a surface of the micro-bubble and containing a drug. The contrast agent of the present invention can be used in both the ultrasound diagnosis and the photoacoustic image diagnosis, and can significantly increase the accuracy of photoacoustic images.Type: GrantFiled: October 13, 2014Date of Patent: February 9, 2021Assignee: IMGT CO, LTD.Inventors: Hyun Cheol Kim, Hyung Won Moon, Jin Ho Chang
-
Patent number: 10912849Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 31, 2018Date of Patent: February 9, 2021Assignee: FIVE ELEVEN PHARMA INC.Inventors: Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
-
Patent number: 10912850Abstract: Radiofluorinated FNDP for PET imaging of soluble epoxide hydrolase (sEH) and method of using the same are disclosed.Type: GrantFiled: May 4, 2017Date of Patent: February 9, 2021Assignees: The Johns Hopkins University, Oregon Health & Science UniversityInventors: Andrew Horti, Martin G. Pomper, Nabil J. Alkayed
-
Patent number: 10912851Abstract: The present invention is directed to an apparatus for receiving, stowing, sterilizing, delivery, and pick-up of a package. In one case, the package can be an unattended package which cannot be received by the consumer. In another case, the package can be a package that has to be disinfected first to be received by the consumer. The apparatus comprises a frame and an enclosure mounted in the frame. The enclosure including one or more storage compartments for receiving and stowing the package. The apparatus further comprises a digital locking feature to control access to the enclosure and UV-lamps for disinfection of the package.Type: GrantFiled: July 1, 2020Date of Patent: February 9, 2021Inventor: Royce Newcomb
-
Patent number: 10912852Abstract: A sterilization system including an oxygen generator, an ozone generator, a mixer, a wash chamber, and a sterilization chamber is disclosed. The oxygen generator is configured to generate a flow of oxygen. The ozone generator is in fluid communication with the oxygen generator, and configured to generate a flow of ozone from the flow of oxygen. The mixer is in fluid communication with the ozone generator and configured to receive the flow of ozone and a flow of cleaning fluid, and mix the flow of ozone into the flow of cleaning fluid, resulting in a flow of ozonated cleaning fluid. The wash chamber is in fluid communication with the mixer and configured to receive the flow of ozonated cleaning fluid from the mixer. The sterilization chamber is in fluid communication with the ozone generator and is configure to receive the flow of ozone.Type: GrantFiled: March 26, 2018Date of Patent: February 9, 2021Assignee: Medaco International Health, LLCInventors: Rex Blakeman, Travis W. Pearse, Jr.
-
Patent number: 10912853Abstract: The present invention relates to a solid pressed air freshener and odor neutralizer composition which can include greater than 10% fragrance. The air freshener comprises a fragrance; preferably the fragrance is impregnated within a water soluble substrate made from a foamed vegetable starch, a surfactant and a solidifier. The solid formulations break down easily in the presence of water and may be sprayed, within the area to be freshened.Type: GrantFiled: December 27, 2018Date of Patent: February 9, 2021Assignee: Ecolab USA Inc.Inventors: Amanda Ruth Blattner, Charles Allen Hodge, Timothy John Kohnke, Mark Dennis Levitt, Julie E. Marquardt
-
Patent number: 10912854Abstract: An incense product and production method thereof. The method may include mixing various incense components together to form a mixture, placing the mixture into an agitator, heating the mixture to form a heated mixture, placing the heated mixture into a tray and allowing the heated mixture to cool to form a cooled mixture, grinding the cooled mixture to a ground mixture, mixing a second set of non-heated plant material in with the ground mixture to form a final mixture, and pressing the final mixture to form a tablet.Type: GrantFiled: October 2, 2018Date of Patent: February 9, 2021Inventor: Eugene Kennedy
-
Patent number: 10912855Abstract: A scent dispenser/absorber includes a pair of cylindrical housing members arranged coaxially about a common longitudinal axis such that the inner housing member is rotatably received in an interior chamber of the outer housing member. Each housing member has a peripheral sidewall provided with a set of radially extending apertures. A scent cartridge is removably disposed within an interior chamber of the inner housing member to absorb undesirable odors, or to emit desirable scents. By manually controlling the relative rotational positions of the housing members, a user can align or misalign the two sets of apertures, thereby enabling or disabling the transfer of scents or odors between the scent cartridge and the surrounding environment.Type: GrantFiled: November 1, 2018Date of Patent: February 9, 2021Assignee: NOVIA PRODUCTS, LLCInventors: William Webster, Randy M. Oliver, David Gallant
-
Patent number: 10912856Abstract: A bacterial adsorption dressing in contact with a wound and a method of manufacturing the bacterial adsorption dressing are provided. A bacterial adsorption dressing with a nonphotocatalyst includes a fabric layer including a polyester fiber as a supporter, and a nonphotocatalyst coating layer formed on the fabric layer and including titanium dioxide phosphate.Type: GrantFiled: September 27, 2017Date of Patent: February 9, 2021Assignee: SAMBO ADVANCED MATERIALS INC.Inventors: Hyung Joon Kim, Jeon Young Kang, Jeong Ha Lee
-
Patent number: 10912857Abstract: A lotion composition is provided. The lotion composition includes a) about 1% to about 90%, by weight, of a rheology structurant; and a b) carrier.Type: GrantFiled: October 17, 2017Date of Patent: February 9, 2021Assignee: The Procter & Gamble CompanyInventors: Robert Ya-lin Pan, Debora Christine Ebert, Peter Christopher Ellingson, Raphael Warren
-
Patent number: 10912858Abstract: This disclosure relates to pectin-based polymer compositions and methods of use thereof to cover, protect, and seal injuries, e.g., surgical wounds, in a mesothelial tissue. The methods include obtaining a bioadhesive pectin-based polymer composition including a complex of high-methoxyl pectin (HMP) and carboxymethylcellulose (CMC) in a ratio from about 10 to 1 to 1 to 10 by weight; applying the composition to an injured mesothelial tissue; and applying pressure for at least one minute to enable the composition to bind to the mesothelial tissue.Type: GrantFiled: April 30, 2018Date of Patent: February 9, 2021Assignee: The Brigham and Women's Hospital, Inc.Inventors: Steven James Mentzer, Cristian David Valenzuela, Alexandra Brooke Ysasi, Andrew Barrett Servais
-
Patent number: 10912859Abstract: Compositions and methods for sealing tissue of a patient in a wet environment are disclosed.Type: GrantFiled: March 7, 2018Date of Patent: February 9, 2021Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Yves A. Delmotte, Jonathan Payssan
-
Patent number: 10912860Abstract: A microporous gel system for certain applications, including biomedical applications, includes an aqueous solution containing plurality of microgel particles including a biodegradable crosslinker. In some aspects, the microgel particles act as gel building blocks that anneal to one another to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. In certain aspects, annealing of the microgel particles occurs after exposure to an annealing agent that is endogenously present or exogenously added. In some embodiments, annealing of the microgel particles requires the presence of an initiator such as exposure to light. In particular embodiments, the chemical and physical properties of the gel building blocks can be controlled to allow downstream control of the resulting assembled scaffold. In one or more embodiments, cells are able to quickly infiltrate the interstitial spaces of the assembled scaffold.Type: GrantFiled: September 11, 2017Date of Patent: February 9, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Donald R. Griffin, Westbrook Weaver, Tatiana Segura, Dino Di Carlo, Philip Scumpia
-
Patent number: 10912861Abstract: Devices and methods for skin graft harvesting are disclosed. In one aspect of the invention, substrates for transplanting skin grafts are disclosed that include a soft-tack, biocompatible composition having a surface adapted to contact at least one excised skin graft and engage the graft for removal from a donor site. In another aspect of the invention, at least a portion of the skin-contacting surface of the substrate (or dressing) is porous to facilitate fluid transport into (or out of) the graft site during harvesting and/or transplantation. The substrates can also incorporate an absorbent component to capture fluids. The substrate can be a mesh or fabric or web, e.g. woven, knitted, nonwoven or molded. The substrate can be a mesh of biocompatible fibers, for example, cellulosic, polyolefins, polyurethanes, polyesters or polyamide fibers. In one embodiment the mesh is formed of cellulose acetate fibers and coated with a silicone gel, to imparted the desire degree of tackiness.Type: GrantFiled: April 11, 2016Date of Patent: February 9, 2021Assignee: KCI LICENSING, INC.Inventors: Kevin Higley, Bradley Jonietz, T. Blane Sanders
-
Patent number: 10912862Abstract: The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects.Type: GrantFiled: February 5, 2013Date of Patent: February 9, 2021Assignees: Children's Medical Center Corporation, Tufts UniversityInventors: Joshua R. Mauney, Carlos R. Estrada, David L. Kaplan, Eun Seok Gil
-
Patent number: 10912863Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.Type: GrantFiled: October 24, 2018Date of Patent: February 9, 2021Assignee: Revivicor, Inc.Inventors: David Ayares, Paul Rohricht